Takeda Aims At BMS’s Sotyktu In $4bn Deal For Nimbus’s TYK2 Inhibitor
Executive Summary
Takeda’s R&D chief Andy Plump said his company has seen data indicating game-changing characteristics for TAK-279 in psoriasis. It plans to bring the candidate into Phase III next year.
You may also be interested in...
Finance Watch: Big Financings Show Investors Remain Interested In Certain Opportunities
A mix of mega-rounds and smaller seed financings show investment happening at both ends of the venture capital spectrum. In public company financings, Gilead prices $2bn note offering, Biogen secures $1.5bn for Reata deal, Inhibrx completes a $200m PIPE and the IPO market shows new signs of life.
J&J/Protagonist’s JNJ-2113 Advancing To Pivotal Psoriasis Trial But Efficacy Questions Remain
The partners’ orally administered IL-23R inhibitor met all primary and secondary endpoints in a Phase IIb plaque psoriasis trial, justifying advancement to Phase III even though its efficacy fell short of available injectables according to cross-trial comparisons.
Record Revenues For Takeda But Headwinds Coming
While Japan's largest pharma company reached a number of milestones last fiscal year, it is facing a number of challenges to revenues in 2023, for which it is looking to its core commercial portfolio and pipeline to help drive growth.